Given the precise role of rhEpo in human cancers, particularly tumor progression and recurrence, is not well understood, clinical and basic research studies are still necessary to define signaling pathways activated by rhEpo/EpoR within nonhematopoietic cancer cells. Here, EPOR is linked to cancer.